Xencor(XNCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XNCR Xencor

Trading 09-18 14:18:52 EDT

24.57

-0.02

-0.08%

High25.02	Low24.13	Vol470.94K
Open24.45	D1 Closing24.59	Amplitude3.64%
Mkt Cap1.82B	Tradable Cap1.33B	Total Shares74.13M
T/O11.59M	T/O Rate0.87%	Tradable Shares54.25M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XNCR","market":"US","secType":"STK","nameCN":"Xencor","latestPrice":24.57,"timestamp":1789755529502,"preClose":24.59,"halted":0,"volume":470938,"delay":0,"changeRate":-0.0008133387555916866,"floatShares":54251400,"shares":74127400,"eps":-2.176824,"marketStatus":"Trading","change":-0.02,"latestTime":"09-18 14:18:52 EDT","open":24.45,"high":25.0228,"low":24.1283,"amount":11587192.137248,"amplitude":0.036377,"askPrice":24.58,"askSize":71,"bidPrice":24.56,"bidSize":28,"shortable":3,"etf":0,"ttmEps":-2.176824,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789761600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1386046800000,"exchange":"NASDAQ","adjPreClose":24.59,"preHourTrading":{"tag":"盘前","latestPrice":24.45,"preClose":24.59,"latestTime":"09:29 EDT","volume":584,"amount":14278.630056,"timestamp":1789738199999,"change":-0.14,"changeRate":-0.005693,"amplitude":0.01708},"postHourTrading":{"tag":"盘后","latestPrice":24.59,"preClose":24.59,"latestTime":"19:30 EDT","volume":8319,"amount":204565.24,"timestamp":1789687804859,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.54412,"impliedVol":1.0584,"impliedVolPercentile":0.8287},"requestUrl":"/m/hq/s/XNCR","defaultTab":"news","newsList":[{"id":"2666520901","title":"Xencor is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2666520901","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666520901?lang=en_us&edition=fundamental","pubTime":"2026-09-11 22:05","pubTimestamp":1789135500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XNCR/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666528709","title":"Xencor price target raised to $35 from $27 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2666528709","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666528709?lang=en_us&edition=fundamental","pubTime":"2026-09-11 17:35","pubTimestamp":1789119321,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Xencor (XNCR) to $35 from $27 and keeps an Overweight rating on the shares. The firm updated the company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xencor-price-target-raised-to-35-from-27-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xencor-price-target-raised-to-35-from-27-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666540057","title":"Xencor (XNCR) Receives a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2666540057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666540057?lang=en_us&edition=fundamental","pubTime":"2026-09-11 17:16","pubTimestamp":1789118192,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on Xencor, with a price target of $35.00. Darout covers the Healthca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/xencor-xncr-receives-a-buy-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/xencor-xncr-receives-a-buy-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XNCR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664877239","title":"Xencor price target raised to $21 from $14 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2664877239","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664877239?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:26","pubTimestamp":1788441990,"startTime":"0","endTime":"0","summary":"JPMorgan analyst Brian Cheng raised the firm’s price target on Xencor (XNCR) to $21 from $14 and keeps a Neutral rating on the shares. The firm upd...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xencor-price-target-raised-to-21-from-14-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xencor-price-target-raised-to-21-from-14-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XNCR","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664826999","title":"Xencor (XNCR) Could Be 6% Below Fair Value On Its Antibody Pipeline Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2664826999","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664826999?lang=en_us&edition=fundamental","pubTime":"2026-09-03 11:27","pubTimestamp":1788406049,"startTime":"0","endTime":"0","summary":"Xencor (XNCR) is drawing fresh attention after management scheduled a presentation at the Cantor Global Healthcare Conference on September 9, 2026, as investors watch for any updates on its antibody pipeline.\nThe recent scheduling of Xencor’s Cantor presentation comes after a sharp shift in sentiment, with the stock giving back some ground in the last week. It has a 7 day share price return of 5.41% and a 1 day share price return of 3.62%, following a strong 30 day share price return of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xncr/xencor/news/xencor-xncr-could-be-6-below-fair-value-on-its-antibody-pipe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xncr/xencor/news/xencor-xncr-could-be-6-below-fair-value-on-its-antibody-pipe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664846019","title":"Xencor to Present at Cantor Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664846019","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664846019?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:01","pubTimestamp":1788379284,"startTime":"0","endTime":"0","summary":"Xencor to present at Cantor Global Healthcare ConferenceXencor will present at the Cantor Global Healthcare Conference on Sept. 9, 2026.The presentation is scheduled for 10:55 a.m. EDT.Disclaimer:This","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL6vZ0d2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664856828","title":"Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2664856828","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664856828?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:49","pubTimestamp":1788263361,"startTime":"0","endTime":"0","summary":"Xencor (XNCR) has an average rating of buy and mean price target of $28.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and re","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XNCR","RJF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659660861","title":"Xencor Advances Dual-Antibody Cancer Trial, Keeping Investor Focus on XNCR","url":"https://stock-news.laohu8.com/highlight/detail?id=2659660861","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659660861?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:31","pubTimestamp":1786638674,"startTime":"0","endTime":"0","summary":"Xencor Inc. ($XNCR) announced an update on their ongoing clinical study. The Phase 1 trial A Phase 1 Trial, Evaluating the Safety and Tolerability ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xencor-advances-dual-antibody-cancer-trial-keeping-investor-focus-on-xncr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xencor-advances-dual-antibody-cancer-trial-keeping-investor-focus-on-xncr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","XNCR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658354779","title":"Analysts’ Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658354779","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658354779?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:50","pubTimestamp":1786362616,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Xencor (XNCR), Revolution Medicines (RVMD) and Roiva...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-xencor-xncr-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-xencor-xncr-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","IDNA","LU0128526141.USD","LU0029874061.USD","IE00BJT1NW94.SGD","IE0009354923.USD","IE0009355771.USD","XNCR","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0109394709.USD","PTH","RVMD","BK4581","LU0889565916.HKD","LABU","BK4137","IE00BJJMRZ35.SGD","BBH","LU0320765992.SGD","XLV","BK4585","CANC","IE00B2B36J28.USD","HCSG","IE00B4R5TH58.HKD","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657629107","title":"Canada's DRI Healthcare Q2 Income Rises, Helped by Milestone Events in Royalty Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2657629107","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657629107?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:12","pubTimestamp":1786137124,"startTime":"0","endTime":"0","summary":"Canada's DRI Healthcare Q2 income rises, helped by milestone events in royalty portfolioOverviewCanada pharmaceutical royalty investor's Q2 total income rose to a record $50.1 mlnAdjusted EBITDA margi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL1N444109:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IHE","LU0566484027.USD","LU1559883803.SGD","PBE","XNCR","IE0009354923.USD","LGND","BK4007","RPRX","BK4139","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657645729","title":"Xenetic Biosciences Q2 Royalty Revenue Rises on Takeda Sublicense","url":"https://stock-news.laohu8.com/highlight/detail?id=2657645729","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657645729?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:44","pubTimestamp":1786106668,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences Q2 royalty revenue rises on Takeda sublicenseOverviewUS biopharma firm's Q2 royalty revenue rose 12% yr/yr, driven by Takeda sublicenseQ2 net loss widened to $0.9 mln from $0.7 mln","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL1N4440HO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IHE","BK4139","XBIO","XNCR","PBE","AGEN","RPRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657570696","title":"Verastem Q2 Revenue Jumps on New Product Sales and Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2657570696","media":"Reuters","labels":["productRelease","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657570696?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:12","pubTimestamp":1786047143,"startTime":"0","endTime":"0","summary":"Verastem Q2 revenue jumps on new product sales and milestoneOverviewU.S. cancer drug maker's Q2 revenue rose sharply yr/yr on new product sales and milestone paymentCompany posted a Q2 net loss, with ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431EJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443382.USD","JDOC","LU2133065610.SGD","LU0289739343.SGD","IYH","LU0553294199.USD","LU0122379950.USD","LU2237443978.SGD","PJP","LU0154245756.USD","AGNG","VSTM","CHRS","LU0069063385.USD","LU1074936037.SGD","FHLC","LU1496350502.SGD","LU0472753341.HKD","RXL","VHT","LU1732799900.SGD","IE0009355771.USD","LU1585245621.USD","SG9999015978.USD","LU2237443549.SGD","LU1037948541.HKD","LU0820561818.USD","LU1496350171.SGD","IXJ","TRUH","FTXH","IE0004445239.USD","IE00BGHQF631.EUR","PPH","MEDX","RGNX","IE00BFTCPJ56.SGD","IE00BLSP4452.SGD","CMI","MADE","XLV","LU2463526074.USD","LU1093756325.SGD","ABBV","LU1839511570.USD","IE00B19Z3B42.SGD","LU0029864427.USD","GLAM","XNCR","IE00BLSP4239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657865582","title":"Xencor Price Target Raised to $30.00/Share from $26.00 by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2657865582","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657865582?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:53","pubTimestamp":1786031580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XNCR/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657653875","title":"Cancer Drugmaker Genmab's H1 Revenue Rises, Lifts FY Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657653875","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657653875?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:12","pubTimestamp":1786029141,"startTime":"0","endTime":"0","summary":"Cancer drugmaker Genmab's H1 revenue rises, lifts FY outlookOverviewDenmark biotech firm's H1 2026 revenue rose 25% yr/yr, driven by higher royalties and salesOperating profit for H1 2026 increased sl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430Z4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","HELX","XNCR","LGND","BK4007","BCRX","BK4139","IE0009354923.USD","LU0566484027.USD","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657637356","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: GoodRx Holdings (GDRX), Xencor (XNCR) and PepGen Inc. (PEPG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657637356","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657637356?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:40","pubTimestamp":1786023641,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GoodRx Holdings (GDRX), Xencor (XNCR) and PepGen I...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-goodrx-holdings-gdrx-xencor-xncr-and-pepgen-inc-pepg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-goodrx-holdings-gdrx-xencor-xncr-and-pepgen-inc-pepg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","XNCR","LU0128526141.USD","PEPG","XBI","HCSG","XLV","BK4139","BK4581","GDRX","BK4167","BK4588","LU0029874061.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657394276","title":"Xencor price target raised to $44 from $43 at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2657394276","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657394276?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:11","pubTimestamp":1786018278,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Steve Seedhouse raised the firm’s price target on Xencor (XNCR) to $44 from $43 and keeps an Overweight rating on the sha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xencor-price-target-raised-to-44-from-43-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xencor-price-target-raised-to-44-from-43-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657364756","title":"RBC Capital Adjusts PT on Xencor to $20 From $19, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657364756","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657364756?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:01","pubTimestamp":1786017704,"startTime":"0","endTime":"0","summary":"Xencor (XNCR) has an average rating of buy and mean price target of $28.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657635177","title":"Agenus Q2 Revenue Rises on Access and Royalty Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2657635177","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657635177?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:44","pubTimestamp":1786016679,"startTime":"0","endTime":"0","summary":"Agenus Q2 revenue rises on access and royalty incomeOverviewImmuno-oncology drug developer's Q2 revenue rose yr/yr, driven by higher royalty and access program revenueAgenus completed $85 mln private ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430L5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS","HELX","LGND","BK4007","BK4139","LU0566484027.USD","AGEN","LU1559883803.SGD","IE0009354923.USD","XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657635574","title":"Regenxbio Q2 Revenue Surges on AbbVie Milestone Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2657635574","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657635574?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:39","pubTimestamp":1786016345,"startTime":"0","endTime":"0","summary":"Regenxbio Q2 revenue surges on AbbVie milestone paymentOverviewGene therapy developer's Q2 revenue surged yr/yr, driven by $100 mln AbbVie milestone paymentCompany posted net income in Q2 after prior-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430IO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN8TJ469.HKD","LU1551013425.SGD","VHT","LU0098860793.USD","GLAM","IE00B2B36J28.USD","SG9999015952.SGD","XLV","IE0004445239.USD","LU0198837287.USD","MEDX","PPH","LU0211328371.USD","LU1061106388.HKD","LU0058720904.USD","LU0985320562.USD","LU1074936037.SGD","RXL","RGNX","LU1267930573.SGD","LU0203345920.USD","LU1057294990.SGD","LU2237443382.USD","LU2089283258.USD","PGEN","IE0002141913.USD","FHLC","LU1093756168.USD","PJP","BK4533","AGNG","LU0432979614.USD","LU0859254822.USD","LU0868494708.USD","IE00B4R5TH58.HKD","ABBV","LU0029864427.USD","SG9999015986.USD","IXJ","LU0310800379.SGD","LU0943347566.SGD","TRUH","FTXH","IE0000B7K699.USD","IYH","JDOC","XNCR","LU0289961442.SGD","LU2237443978.SGD","LU1244550221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638230","title":"Aclaris Therapeutics Q2 Revenue Beats Analyst Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638230","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638230?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:10","pubTimestamp":1786014603,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Q2 revenue beats analyst estimatesOverviewU.S. biopharma's Q2 revenue fell yr/yr but beat analyst expectationsNet loss for Q2 widened and missed analyst estimatesCompany reaffirme","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XNCR","BK4007","BK0046","300485","VNDA","BK0239","BK4139","ACRS","ELVN","BK0028","BK0012"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xencor.com","stockEarnings":[{"period":"1week","weight":0.0136},{"period":"1month","weight":-0.0323},{"period":"3month","weight":0.9454},{"period":"6month","weight":1.0272},{"period":"1year","weight":1.6584},{"period":"ytd","weight":0.6061}],"compareEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":-0.0063},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1758},{"period":"1year","weight":0.1569},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.230769,"avgChangeRate":-0.060713},{"month":2,"riseRate":0.615385,"avgChangeRate":0.046082},{"month":3,"riseRate":0.230769,"avgChangeRate":-0.051854},{"month":4,"riseRate":0.153846,"avgChangeRate":-0.035695},{"month":5,"riseRate":0.538462,"avgChangeRate":0.016528},{"month":6,"riseRate":0.615385,"avgChangeRate":0.108196},{"month":7,"riseRate":0.615385,"avgChangeRate":0.020771},{"month":8,"riseRate":0.461538,"avgChangeRate":0.012524},{"month":9,"riseRate":0.384615,"avgChangeRate":0.007818},{"month":10,"riseRate":0.5,"avgChangeRate":0.005748},{"month":11,"riseRate":0.916667,"avgChangeRate":0.149173},{"month":12,"riseRate":0.5,"avgChangeRate":0.005588}],"exchange":"NASDAQ","name":"Xencor","nameEN":"Xencor"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xencor(XNCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xencor(XNCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xencor,XNCR,Xencor股票,Xencor股票老虎,Xencor股票老虎国际,Xencor行情,Xencor股票行情,Xencor股价,Xencor股市,Xencor股票价格,Xencor股票交易,Xencor股票购买,Xencor股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xencor(XNCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xencor(XNCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}